News for Soligenix, Inc. (0A6I.L)

In recent stock market news, Soligenix (SNGX) has been the focus of analysts from Alliance Global Partners. On July 16, 2025, analyst James Molloy released an u

**media[647780]**

PR NewswirePRINCETON, N.J., May 9, 2025 PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stag

Soligenix (SNGX) reported a net loss of $3.2 million in Q1 2025, compared to $1.9 million in Q1 2024. The company recorded no revenue for Q1 2025, down

PR NewswirePRINCETON, N.J., April 14, 2025 Interim Results from FDA-Funded Study Reinforces HyBryte'sâ„¢ Rapid Response and Strong Safety ProfilePRINCETON,

Soligenix, Inc. (SNGX) has revealed interim findings from an ongoing study assessing the effectiveness of prolonged HyBryte treatment over 54 weeks in patients

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN ”“ Soligenix Inc. ( SNGX), a late-stage biopharmaceutical company focused on developing and commerc

PR NewswirePRINCETON, N.J., March 25, 2025 Broader protection induced by combination of COVID adenovirus vaccine plus CiVaxâ„¢ compared to 2-shot mRNA vacc

PR NewswirePRINCETON, N.J., Jan. 16, 2025 PRINCETON, N.J., Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-

PR NewswirePRINCETON, N.J., Dec. 16, 2024 FLASH2 Study opens patient enrollmentPRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX

PR NewswirePRINCETON, N.J., Dec. 2, 2024 Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryteâ„¢PRINCETON, N.J., Dec. 2, 2024 /PRNews

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix gains Hong Kong patent for synthetic hypericin

Soligenix secures amended loan terms with Pontifax Medison

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Shares of Levi Strauss & Co. LEVI fell sharply in today's pre-market trading following third-quarter results. Levi Strauss posted better-than-expected earnings...

Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone

China-based financial services business Sentage Holdings Inc. (SNTG) is up over 59 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.